Edwards Lifesciences Co. (NYSE:EW) Given Average Recommendation of “Hold” by Brokerages

Edwards Lifesciences Co. ( NYSE:EW – Get Free Report ) has earned a consensus rating of “Hold” from the twenty-four analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation and ten have given a buy recommendation to the company.

The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $78.55. EW has been the subject of a number of analyst reports.



Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th.

Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th.

Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th.

Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Finally, Barclays increased their price target on Edwards Lifesciences from $88.00 to $90.

00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. View Our Latest Research Report on Edwards Lifesciences Insiders Place Their Bets Institutional Inflows and Outflows Several institutional investors have recently modified their holdings of EW. Crowley Wealth Management Inc.

bought a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $29,000.

Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $30,000. Finally, Park Square Financial Group LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $44,000.

79.46% of the stock is currently owned by institutional investors and hedge funds. Edwards Lifesciences Stock Performance Shares of Edwards Lifesciences stock opened at $71.

56 on Friday. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $95.

25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.

89 and a current ratio of 3.46. The stock has a market capitalization of $42.

07 billion, a price-to-earnings ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.

15. The firm has a fifty day moving average of $71.31 and a two-hundred day moving average of $70.

85. Edwards Lifesciences ( NYSE:EW – Get Free Report ) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.

59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04.

Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

As a group, equities research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year. Edwards Lifesciences Company Profile ( Get Free Report Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.

It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. Featured Stories Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter .

.